B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterised by abnormalities of the "B-cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms.
United States, Alabama
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35294
United States, California
UCLA Ronald Reagan Medical Center, Los Angeles, California, United States, 90095
Stanford Cancer Institute, Palo Alto, California, United States, 94304
United States, Iowa
University of Iowa, Iowa City, Iowa, United States, 52242
United States, Kansas
The University of Kansas Medical Center, Westwood, Kansas, United States, 66205
United States, Kentucky
Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States, 40207
United States, Nebraska
University of Nebraska Medical Center, Omaha, Nebraska, United States, 68198
United States, New Jersey
Hackensack University Medical Center, Hackensack, New Jersey, United States, 07601
United States, New York
Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10021
United States, Oregon
Oregon Health & Sciences University, Portland, Oregon, United States, 97239
United States, Texas
MD Anderson Cancer Center, Houston, Texas, United States, 77030
United States, Wisconsin
University of Wisconsin-Madison, Madison, Wisconsin, United States, 53705
B-cell lymphoma disease informationFrequency of B-cell lymphomaFT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical TrialThe Role of Gene Editing Within CAR T-Cell Therapy Development - Interview with Professor Waseem QasimOff-the-shelf Cell-based Cancer Immunotherapy Developing First-of-kind Cell Products using Clonal Master iPSC LinesGene-Editing Clinical Trial Update
Status: Active recruiting
Description
This is a Phase I dose-finding study of FT819, either as monotherapy or in combination with IL-2 in subjects with relapsed/refractory B-cell lymphoma, chronic lymphocytic leukaemia and precursor B-cell acute lymphoblastic leukaemia (B-ALL). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
FT819 is developed using precise genetic engineering and multiple targeting events at the single cell level, and it is derived from a clonally-derived master cell bank (MCB) that serves as the starting material to support consistent and reproducible clinical manufacturing. The engineered features of FT819 include the targeted integration of a novel CD19 1XX-CAR into the T cell receptor α constant (TRAC) locus to provide antigen specificity, enhanced efficacy and temporally-regulated CAR expression driven by an endogenous (TCR) promoter. Such features are designed to also eliminate the possibility of graft versus host disease (GvHD) by nullifying the TCR.
Last updated: Jun. 5, 2023